Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy

Patients with advanced heart failure (AHF) who are not candidates to advanced therapies have poor prognosis. Some trials have shown that intermittent levosimendan can reduce HF hospitalizations in AHF in the short term. In this real-life registry, we describe the patterns of use, safety and factors...

Descripción completa

Detalles Bibliográficos
Autores: Dobarro, David|||0000-0003-0716-254X, Donoso-Trenado, Víctor, Solé González, Eduard|||0000-0002-5727-9925, Moliner-Abós, Carles|||0000-0002-9264-5804, García Pinilla, José Manuel|||0000-0001-5999-5741, Lopez-Fernandez, Silvia|||0000-0002-2461-8492, Ruiz Bustillo, Sonia|||0000-0002-6074-914X, Díez-López, Carles|||0000-0002-3734-4777, Castrodeza, Javier|||0000-0002-4779-6849, Méndez-Fernández, Ana B., Vaqueriza-Cubillo, David|||0000-0002-8207-7604, Cobo-Marcos, M.|||0000-0002-9026-061X, Tobar, Javier, Sagasti-Aboitiz, Igor, Rodriguez, Miguel, Escolar, Vanessa, Abecia, Ana, Codina, Pau|||0000-0002-2469-5711, Gómez-Otero, Inés, Pastor, Francisco|||0000-0002-9818-2409, Marzoa-Rivas, Raquel, González-Babarro, Eva, de Juan-Baguda, Javier, Melendo-Viu, María, De Frutos, Fernando|||0000-0003-4350-3217, González-Costello, José|||0000-0002-7437-3630
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:301691
Acceso en línea:https://ddd.uab.cat/record/301691
https://dx.doi.org/urn:doi:10.1002/ehf2.14278
Access Level:acceso abierto
Palabra clave:Advanced heart failure
Inotropes
Levosimendan
Palliative care
id ES_b671dbc0175b7d51285b7d3166af38f0
oai_identifier_str oai:ddd.uab.cat:301691
network_acronym_str ES
network_name_str España
repository_id_str
spelling Intermittent inotropic support with levosimendan in advanced heart failure as destination therapyThe LEVO-D registryDobarro, David|||0000-0003-0716-254XDonoso-Trenado, VíctorSolé González, Eduard|||0000-0002-5727-9925Moliner-Abós, Carles|||0000-0002-9264-5804García Pinilla, José Manuel|||0000-0001-5999-5741Lopez-Fernandez, Silvia|||0000-0002-2461-8492Ruiz Bustillo, Sonia|||0000-0002-6074-914XDíez-López, Carles|||0000-0002-3734-4777Castrodeza, Javier|||0000-0002-4779-6849Méndez-Fernández, Ana B.Vaqueriza-Cubillo, David|||0000-0002-8207-7604Cobo-Marcos, M.|||0000-0002-9026-061XTobar, JavierSagasti-Aboitiz, IgorRodriguez, MiguelEscolar, VanessaAbecia, AnaCodina, Pau|||0000-0002-2469-5711Gómez-Otero, InésPastor, Francisco|||0000-0002-9818-2409Marzoa-Rivas, RaquelGonzález-Babarro, Evade Juan-Baguda, JavierMelendo-Viu, MaríaDe Frutos, Fernando|||0000-0003-4350-3217González-Costello, José|||0000-0002-7437-3630Advanced heart failureInotropesLevosimendanPalliative carePatients with advanced heart failure (AHF) who are not candidates to advanced therapies have poor prognosis. Some trials have shown that intermittent levosimendan can reduce HF hospitalizations in AHF in the short term. In this real-life registry, we describe the patterns of use, safety and factors related to the response to intermittent levosimendan infusions in AHF patients not candidates to advanced therapies. Multicentre retrospective study of patients diagnosed with advanced heart failure, not HT or LVAD candidates. Patients needed to be on the optimal medical therapy according to their treating physician. Patients with de novo heart failure or who underwent any procedure that could improve prognosis were not included in the registry. Four hundred three patients were included; 77.9% needed at least one admission the year before levosimendan was first administered because of heart failure. Death rate at 1 year was 26.8% and median survival was 24.7 [95% CI: 20.4-26.9] months, and 43.7% of patients fulfilled the criteria for being considered a responder lo levosimendan (no death, heart failure admission or unplanned HF visit at 1 year after first levosimendan administration). Compared with the year before there was a significant reduction in HF admissions (38.7% vs. 77.9%; P < 0.0001), unplanned HF visits (22.7% vs. 43.7%; P < 0.0001) or the combined event including deaths (56.3% vs. 81.4%; P < 0.0001) during the year after. We created a score that helps predicting the responder status at 1 year after levosimendan, resulting in a score summatory of five variables: TEER (+2), treatment with beta-blockers (+1.5), Haemoglobin.Universitat Autònoma de Barcelona 22023-01-0120232023-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/301691https://dx.doi.org/urn:doi:10.1002/ehf2.14278reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3016912026-06-06T12:50:31Z
dc.title.none.fl_str_mv Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy
The LEVO-D registry
title Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy
spellingShingle Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy
Dobarro, David|||0000-0003-0716-254X
Advanced heart failure
Inotropes
Levosimendan
Palliative care
title_short Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy
title_full Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy
title_fullStr Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy
title_full_unstemmed Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy
title_sort Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy
dc.creator.none.fl_str_mv Dobarro, David|||0000-0003-0716-254X
Donoso-Trenado, Víctor
Solé González, Eduard|||0000-0002-5727-9925
Moliner-Abós, Carles|||0000-0002-9264-5804
García Pinilla, José Manuel|||0000-0001-5999-5741
Lopez-Fernandez, Silvia|||0000-0002-2461-8492
Ruiz Bustillo, Sonia|||0000-0002-6074-914X
Díez-López, Carles|||0000-0002-3734-4777
Castrodeza, Javier|||0000-0002-4779-6849
Méndez-Fernández, Ana B.
Vaqueriza-Cubillo, David|||0000-0002-8207-7604
Cobo-Marcos, M.|||0000-0002-9026-061X
Tobar, Javier
Sagasti-Aboitiz, Igor
Rodriguez, Miguel
Escolar, Vanessa
Abecia, Ana
Codina, Pau|||0000-0002-2469-5711
Gómez-Otero, Inés
Pastor, Francisco|||0000-0002-9818-2409
Marzoa-Rivas, Raquel
González-Babarro, Eva
de Juan-Baguda, Javier
Melendo-Viu, María
De Frutos, Fernando|||0000-0003-4350-3217
González-Costello, José|||0000-0002-7437-3630
author Dobarro, David|||0000-0003-0716-254X
author_facet Dobarro, David|||0000-0003-0716-254X
Donoso-Trenado, Víctor
Solé González, Eduard|||0000-0002-5727-9925
Moliner-Abós, Carles|||0000-0002-9264-5804
García Pinilla, José Manuel|||0000-0001-5999-5741
Lopez-Fernandez, Silvia|||0000-0002-2461-8492
Ruiz Bustillo, Sonia|||0000-0002-6074-914X
Díez-López, Carles|||0000-0002-3734-4777
Castrodeza, Javier|||0000-0002-4779-6849
Méndez-Fernández, Ana B.
Vaqueriza-Cubillo, David|||0000-0002-8207-7604
Cobo-Marcos, M.|||0000-0002-9026-061X
Tobar, Javier
Sagasti-Aboitiz, Igor
Rodriguez, Miguel
Escolar, Vanessa
Abecia, Ana
Codina, Pau|||0000-0002-2469-5711
Gómez-Otero, Inés
Pastor, Francisco|||0000-0002-9818-2409
Marzoa-Rivas, Raquel
González-Babarro, Eva
de Juan-Baguda, Javier
Melendo-Viu, María
De Frutos, Fernando|||0000-0003-4350-3217
González-Costello, José|||0000-0002-7437-3630
author_role author
author2 Donoso-Trenado, Víctor
Solé González, Eduard|||0000-0002-5727-9925
Moliner-Abós, Carles|||0000-0002-9264-5804
García Pinilla, José Manuel|||0000-0001-5999-5741
Lopez-Fernandez, Silvia|||0000-0002-2461-8492
Ruiz Bustillo, Sonia|||0000-0002-6074-914X
Díez-López, Carles|||0000-0002-3734-4777
Castrodeza, Javier|||0000-0002-4779-6849
Méndez-Fernández, Ana B.
Vaqueriza-Cubillo, David|||0000-0002-8207-7604
Cobo-Marcos, M.|||0000-0002-9026-061X
Tobar, Javier
Sagasti-Aboitiz, Igor
Rodriguez, Miguel
Escolar, Vanessa
Abecia, Ana
Codina, Pau|||0000-0002-2469-5711
Gómez-Otero, Inés
Pastor, Francisco|||0000-0002-9818-2409
Marzoa-Rivas, Raquel
González-Babarro, Eva
de Juan-Baguda, Javier
Melendo-Viu, María
De Frutos, Fernando|||0000-0003-4350-3217
González-Costello, José|||0000-0002-7437-3630
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Advanced heart failure
Inotropes
Levosimendan
Palliative care
topic Advanced heart failure
Inotropes
Levosimendan
Palliative care
description Patients with advanced heart failure (AHF) who are not candidates to advanced therapies have poor prognosis. Some trials have shown that intermittent levosimendan can reduce HF hospitalizations in AHF in the short term. In this real-life registry, we describe the patterns of use, safety and factors related to the response to intermittent levosimendan infusions in AHF patients not candidates to advanced therapies. Multicentre retrospective study of patients diagnosed with advanced heart failure, not HT or LVAD candidates. Patients needed to be on the optimal medical therapy according to their treating physician. Patients with de novo heart failure or who underwent any procedure that could improve prognosis were not included in the registry. Four hundred three patients were included; 77.9% needed at least one admission the year before levosimendan was first administered because of heart failure. Death rate at 1 year was 26.8% and median survival was 24.7 [95% CI: 20.4-26.9] months, and 43.7% of patients fulfilled the criteria for being considered a responder lo levosimendan (no death, heart failure admission or unplanned HF visit at 1 year after first levosimendan administration). Compared with the year before there was a significant reduction in HF admissions (38.7% vs. 77.9%; P < 0.0001), unplanned HF visits (22.7% vs. 43.7%; P < 0.0001) or the combined event including deaths (56.3% vs. 81.4%; P < 0.0001) during the year after. We created a score that helps predicting the responder status at 1 year after levosimendan, resulting in a score summatory of five variables: TEER (+2), treatment with beta-blockers (+1.5), Haemoglobin.
publishDate 2023
dc.date.none.fl_str_mv 2
2023-01-01
2023
2023-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/301691
https://dx.doi.org/urn:doi:10.1002/ehf2.14278
url https://ddd.uab.cat/record/301691
https://dx.doi.org/urn:doi:10.1002/ehf2.14278
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417446951092224
score 15.81155